[go: up one dir, main page]

BE2019C523I2 - - Google Patents

Download PDF

Info

Publication number
BE2019C523I2
BE2019C523I2 BE2019C523C BE2019C523C BE2019C523I2 BE 2019C523 I2 BE2019C523 I2 BE 2019C523I2 BE 2019C523 C BE2019C523 C BE 2019C523C BE 2019C523 C BE2019C523 C BE 2019C523C BE 2019C523 I2 BE2019C523 I2 BE 2019C523I2
Authority
BE
Belgium
Application number
BE2019C523C
Other languages
Dutch (nl)
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36337298&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE2019C523(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of BE2019C523I2 publication Critical patent/BE2019C523I2/nl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
BE2019C523C 2004-11-12 2019-05-07 BE2019C523I2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62727704P 2004-11-12 2004-11-12
PCT/US2005/041205 WO2006053299A2 (en) 2004-11-12 2005-11-14 Site-directed modification of fviii

Publications (1)

Publication Number Publication Date
BE2019C523I2 true BE2019C523I2 (de) 2025-02-10

Family

ID=36337298

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2019C523C BE2019C523I2 (de) 2004-11-12 2019-05-07

Country Status (32)

Country Link
US (4) US7632921B2 (de)
EP (9) EP3323829B1 (de)
JP (5) JP2008524117A (de)
KR (7) KR101483917B1 (de)
CN (6) CN105148287B (de)
AU (1) AU2005304622B2 (de)
BE (1) BE2019C523I2 (de)
BR (2) BRPI0517795B8 (de)
CA (1) CA2586379C (de)
CY (3) CY1119292T1 (de)
DK (3) DK2371856T3 (de)
ES (4) ES2821832T3 (de)
FR (1) FR19C1031I2 (de)
HN (1) HN2007015683A (de)
HR (2) HRP20070268B1 (de)
HU (5) HUE059193T2 (de)
IL (3) IL182903A (de)
LT (5) LT1824988T (de)
LU (1) LUC00118I2 (de)
MA (1) MA29663B1 (de)
MX (3) MX350293B (de)
NL (1) NL300989I2 (de)
NO (3) NO345800B1 (de)
NZ (1) NZ555032A (de)
PH (2) PH12014500352B1 (de)
PL (3) PL1824988T3 (de)
PT (4) PT2363414T (de)
RU (1) RU2423380C2 (de)
SI (4) SI2363414T1 (de)
UA (1) UA95225C2 (de)
WO (1) WO2006053299A2 (de)
ZA (1) ZA200703696B (de)

Families Citing this family (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2338333B1 (de) 2003-04-09 2017-09-06 ratiopharm GmbH Glycopegylierungsverfahren und durch die Verfahren hergestellte Proteine/Peptide
US9005625B2 (en) 2003-07-25 2015-04-14 Novo Nordisk A/S Antibody toxin conjugates
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
ES2390082T5 (es) * 2004-06-30 2018-01-19 Nektar Therapeutics Conjugados de resto de Factor IX y polímeros
WO2006010143A2 (en) 2004-07-13 2006-01-26 Neose Technologies, Inc. Branched peg remodeling and glycosylation of glucagon-like peptide-1 [glp-1]
HUE026826T2 (en) 2004-10-29 2016-07-28 Ratiopharm Gmbh Modeling and glycopegylation of fibroblast growth factor (FGF)
ES2821832T3 (es) 2004-11-12 2021-04-27 Bayer Healthcare Llc Modificación de FVIII dirigida al sitio
EP2514757A3 (de) 2005-01-10 2014-03-05 ratiopharm GmbH Glycopegylierter Granulozyten-Kolonie stimulierende Faktor
EP2386571B1 (de) 2005-04-08 2016-06-01 ratiopharm GmbH Zusammensetzungen und Verfahren zur Herstellung von Glycosylierungsmutanten eines Proteaseresistenten menschlichen Wachstumshormons
EP1893632B1 (de) 2005-06-17 2015-08-12 Novo Nordisk Health Care AG Selektive reduktion und derivatisierung manipulierter faktor vii proteine mit mindestens einem nichtnativen zystein
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
US20090048440A1 (en) 2005-11-03 2009-02-19 Neose Technologies, Inc. Nucleotide Sugar Purification Using Membranes
AU2007253264A1 (en) * 2006-05-24 2007-11-29 Novo Nordisk Health Care Ag Factor IX analogues having prolonged in vivo half life
US20080280818A1 (en) 2006-07-21 2008-11-13 Neose Technologies, Inc. Glycosylation of peptides via o-linked glycosylation sequences
WO2008057683A2 (en) 2006-10-03 2008-05-15 Novo Nordisk A/S Methods for the purification of polypeptide conjugates
EP2101821B1 (de) 2006-12-15 2014-08-13 Baxter International Inc. Faktor-viia-(poly)sialsäurekonjugat mit verlängerter in-vivo-halbwertszeit
PL2144923T3 (pl) 2007-04-03 2013-12-31 Biogenerix Ag Sposoby leczenia z użyciem glikopegilowanego G-CSF
US9493499B2 (en) 2007-06-12 2016-11-15 Novo Nordisk A/S Process for the production of purified cytidinemonophosphate-sialic acid-polyalkylene oxide (CMP-SA-PEG) as modified nucleotide sugars via anion exchange chromatography
US8173597B2 (en) * 2007-11-09 2012-05-08 Baxter International Inc. Modified recombinant factor VIII and von Willebrand factor and methods of use
EP2257311B1 (de) * 2008-02-27 2014-04-16 Novo Nordisk A/S Konjugierte faktor-viii-moleküle
JP5997443B2 (ja) 2008-05-16 2016-09-28 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ 標的化凝固因子およびそれを使用する方法
AU2009256093A1 (en) * 2008-06-04 2009-12-10 Bayer Healthcare Llc FVIII muteins for treatment of von Willebrand disease
EP2291523B1 (de) 2008-06-24 2014-12-17 CSL Behring GmbH Faktor VIII, Von-Willebrand-Faktor oder Komplexe davon mit verlängerter in-vivo-Halbwertzeit
WO2010019263A2 (en) * 2008-08-15 2010-02-18 Genzyme Corporation Soluble flt constructs for treating cancers
SMT201800486T1 (it) * 2008-10-17 2018-11-09 Baxalta Inc Fattori sanguigni modificati comprendenti un grado basso di polimero solubile in acqua
JP2012508172A (ja) * 2008-11-03 2012-04-05 バイエル・ヘルスケア・エルエルシー 血友病の治療方法
JP2012510060A (ja) * 2008-11-24 2012-04-26 バイエル・ヘルスケア・エルエルシー シリカをベースとする活性化部分トロンボプラスチン時間アッセイにおけるｐｅｇ化血液凝固因子の活性の測定方法
CA2748662A1 (en) * 2009-01-19 2010-07-22 Bayer Healthcare Llc Protein conjugate having an endopeptidase-cleavable bioprotective moiety
CN108530543B (zh) 2009-02-03 2023-06-23 阿穆尼克斯制药公司 延伸重组多肽和包含该延伸重组多肽的组合物
US20110306551A1 (en) * 2009-02-19 2011-12-15 Novo Nordisk A/S Modification of Factor VIII
WO2010107256A2 (en) * 2009-03-20 2010-09-23 Hanmi Pharm. Co., Ltd. Method for preparing a site-specific physiologically active polypeptide conjugate
CN102427823A (zh) * 2009-03-24 2012-04-25 拜耳医药保健有限公司 因子viii变体及使用方法
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
CN104530182A (zh) 2009-07-27 2015-04-22 利普森技术有限公司 非凝血蛋白的糖基多唾液酸化
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
SG178051A1 (en) 2009-07-27 2012-03-29 Lipoxen Technologies Ltd Glycopolysialylation of non-blood coagulation proteins
RU2595442C2 (ru) 2009-07-27 2016-08-27 Баксалта Инкорпорейтед Конъюгаты белков свертывания крови
US9062299B2 (en) 2009-08-24 2015-06-23 Amunix Operating Inc. Coagulation factor IX compositions and methods of making and using same
HRP20180135T1 (hr) 2009-12-06 2018-04-06 Bioverativ Therapeutics Inc. Kimerni i hibridni polipeptidi čimbenika viii-fc, te postupci njihove upotrebe
WO2011075185A1 (en) 2009-12-18 2011-06-23 Oligasis Targeted drug phosphorylcholine polymer conjugates
WO2011101242A1 (en) 2010-02-16 2011-08-25 Novo Nordisk A/S Factor viii molecules with reduced vwf binding
PT2536399T (pt) * 2010-02-21 2020-02-06 Bayer Healthcare Llc Método para ativação e conjugação de biomoléculas
WO2011130694A2 (en) 2010-04-15 2011-10-20 Oligasis High molecular weight zwitterion-containing polymers
GB201007357D0 (en) * 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIII
GB201007356D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIIa
EP3508573A1 (de) 2010-07-09 2019-07-10 Bioverativ Therapeutics Inc. Systeme für faktor viii-verarbeitung und verfahren davon
CA2816575C (en) * 2010-11-05 2019-06-11 Baxter Healthcare S.A. A new variant of antihemophilic factor viii having increased specific activity
CN103282045A (zh) * 2010-12-16 2013-09-04 诺沃—诺迪斯克有限公司 因子viii水溶液
CA2822591C (en) 2010-12-22 2020-12-29 Baxter International Inc. Materials and methods for conjugating a water soluble fatty acid derivative to a protein
EP3808378A1 (de) * 2011-05-27 2021-04-21 Baxalta GmbH Therapeutische proteine mit erhöhter halbwertzeit und verfahren zur herstellung davon
DK2717898T3 (en) 2011-06-10 2019-03-25 Bioverativ Therapeutics Inc COAGULATING COMPOUNDS AND PROCEDURES FOR USE THEREOF
HK1199889A1 (en) 2011-07-01 2015-07-24 Bayer Intellectual Property Gmbh Relaxin fusion polypeptides and uses thereof
CN107261122A (zh) 2011-07-08 2017-10-20 比奥贝拉蒂治疗公司 因子viii嵌合和杂合多肽及其使用方法
AR088161A1 (es) 2011-09-23 2014-05-14 Novo Nordisk As Analogos de glucagon
KR20130049671A (ko) * 2011-11-04 2013-05-14 한미사이언스 주식회사 생리활성 폴리펩타이드 결합체 제조 방법
BR112014019901A8 (pt) 2012-02-15 2018-01-02 Biogen Idec Inc Proteínas de fator viii recombinante
EP3564260B1 (de) 2012-02-15 2022-10-19 Bioverativ Therapeutics Inc. Faktor-viii-zusammensetzungen und verfahren zur herstellung und verwendung davon
US9458223B2 (en) 2012-02-15 2016-10-04 Csl Behring Gmbh Von willebrand factor variants having improved factor VIII binding affinity
EP2666782A1 (de) 2012-05-22 2013-11-27 Imnate Sarl Gerinnungsfaktor VII mit reduzierter Immunogenität
CN104519897A (zh) 2012-06-08 2015-04-15 比奥根艾迪克Ma公司 促凝血化合物
EP3404105A1 (de) 2012-07-06 2018-11-21 Bioverativ Therapeutics Inc. Einkettige faktor-viii-polypeptide exprimierende zelllinie und verwendungen davon
CA2888806A1 (en) 2012-10-18 2014-04-24 Biogen Idec Ma Inc. Methods of using a fixed dose of a clotting factor
EP3943102A1 (de) 2012-10-30 2022-01-26 Bioverativ Therapeutics Inc. Verfahren zur verwendung von fviii-polypeptid
EP2970430A4 (de) * 2013-03-15 2017-01-11 Bayer HealthCare LLC Formulierungen des rekombinanten faktors viii
HUE047933T2 (hu) 2013-03-15 2020-05-28 Bioverativ Therapeutics Inc Faktor VIII polipeptid készítmények
JP6387392B2 (ja) 2013-03-15 2018-09-05 バイオベラティブ セラピューティクス インコーポレイテッド 第ｉｘ因子ポリペプチド製剤
SI2986313T1 (sl) 2013-04-18 2019-09-30 Novo Nordisk A/S Stabilni koagonisti GLP-1 / glukagonskega receptorja z dolgotrajnim učinkom za medicinsko uporabo
DK2796145T3 (da) 2013-04-22 2018-01-29 Csl Ltd Et kovalent kompleks af von Willebrand-faktor og faktor VIII linket af en disulfidbro
TW201519900A (zh) * 2013-04-28 2015-06-01 Bayer Healthcare Llc 用於誘導對凝血因子蛋白之免疫耐受性的組成物及方法
TWI667255B (zh) 2013-08-14 2019-08-01 美商生物化學醫療公司 因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途
EP4108254A1 (de) 2013-08-14 2022-12-28 Bioverativ Therapeutics Inc. Rekombinante faktor-viii-proteine
PT3041513T (pt) 2013-09-08 2020-09-07 Kodiak Sciences Inc Conjugados de polímeros zwiteriónicos com fator viii
AU2014339034A1 (en) * 2013-10-22 2016-05-19 Dbv Technologies Method of treating haemophilia by inducing tolerance to blood factors
US10584147B2 (en) 2013-11-08 2020-03-10 Biovertiv Therapeutics Inc. Procoagulant fusion compound
RU2546297C1 (ru) * 2013-11-19 2015-04-10 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт фармакологии" Сибирского отделения Российской академии медицинских наук Средство, улучшающее реологические свойства крови
EP4332839A3 (de) 2013-12-06 2024-06-05 Bioverativ Therapeutics Inc. Pharmakokinetische werkzeuge für populationen und verwendungen davon
US10822393B2 (en) 2014-01-20 2020-11-03 Octapharma Ag Process for manufacturing factor VIII having an improved ratio of FVIII:C/FVIII/AG
WO2015120056A1 (en) 2014-02-04 2015-08-13 Biogen Ma Inc. Use of cation-exchange chromatography in the flow-through mode to enrich post-translational modifications
EP3114138B1 (de) * 2014-03-05 2021-11-17 Pfizer Inc. Verbesserte muteine von gerinnungsfaktor viii
WO2015148444A1 (en) 2014-03-24 2015-10-01 Biogen Ma Inc. Lyophilized factor ix formulations
CA2944909A1 (en) * 2014-04-04 2015-10-08 Bloodworks Routine laboratory and point-of-care (poc) testing for hemostasis
KR20160144429A (ko) 2014-04-10 2016-12-16 바이엘 헬쓰케어 엘엘씨 배합된 배지 분말 제형 및 세포 배양을 위한 액체 배지의 제조 방법
CN106536547A (zh) 2014-06-04 2017-03-22 诺和诺德股份有限公司 用于医疗用途的glp‑1/胰高血糖素受体共激动剂
KR20170026580A (ko) 2014-07-02 2017-03-08 씨에스엘 리미티드 변형된 폰 빌레브란트 인자
MA40864A (fr) 2014-10-31 2017-09-05 Biogen Ma Inc Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères
CN107406493B (zh) 2015-03-06 2021-08-13 康诺贝林伦瑙有限公司 具有改善的半衰期的经修饰的血管性血友病因子
WO2016188907A1 (en) 2015-05-22 2016-12-01 Csl Behring Recombinant Facility Ag Truncated von willebrand factor polypeptides for treating hemophilia
CA2986625A1 (en) 2015-05-22 2016-12-01 Csl Behring Recombinant Facility Ag Methods for preparing modified von willebrand factor
IL257231B (en) 2015-08-03 2022-09-01 Bioverativ Therapeutics Inc Factor ix fusion proteins and methods of making and using same
US9849125B1 (en) 2015-11-03 2017-12-26 Banner Lifie Sciences LLC Anti-overingestion dosage forms
CA3008448A1 (en) 2016-01-07 2017-07-13 Csl Behring Recombinant Facility Ag Mutated von willebrand factor
KR20180094114A (ko) 2016-01-07 2018-08-22 체에스엘 베링 리컴비넌트 퍼실리티 아게 돌연변이된 절단된 폰 빌레브란트 인자
WO2017222330A1 (ko) * 2016-06-24 2017-12-28 재단법인 목암생명과학연구소 재조합 단쇄 fviii 및 그 화학 접합물
DK3538134T3 (da) 2016-11-11 2022-02-07 CSL Behring Lengnau AG Trunkeret von willebrand-faktor polypeptider til ekstravaskulær administration til behandling eller profylakse af en blodkoagulationsforstyrrelse
SG10201912360SA (en) 2016-11-11 2020-02-27 CSL Behring Lengnau AG Truncated von willebrand factor polypeptides for treating hemophilia
TW201831508A (zh) 2016-11-16 2018-09-01 美商拜耳保健有限責任公司 紅血球標靶因子ｖｉｉｉ及其使用方法
EP3548066A1 (de) 2016-12-02 2019-10-09 Bioverativ Therapeutics Inc. Verfahren zur behandlung von hämophile arthropathie unter verwendung chimärer gerinnungsfaktoren
US12257288B2 (en) 2016-12-02 2025-03-25 Bioverativ Therapeutics Inc. Methods of inducing immune tolerance to clotting factors
KR20190112763A (ko) 2017-01-31 2019-10-07 바이오버라티브 테라퓨틱스 인크. 인자 ix 융합 단백질 및 이의 제조 및 사용 방법
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
KR20190086269A (ko) * 2018-01-12 2019-07-22 재단법인 목암생명과학연구소 체내 지속형 재조합 당단백질 및 이의 제조방법
EP3816181A4 (de) 2018-05-18 2022-04-20 Zhengzhou Gensciences Inc. Verbessertes fviii-fusionsprotein und seine verwendung
HRP20250709T1 (hr) 2018-05-18 2025-08-15 Bioverativ Therapeutics Inc. Postupci liječenja hemofilije a
US11912784B2 (en) 2019-10-10 2024-02-27 Kodiak Sciences Inc. Methods of treating an eye disorder
WO2021091881A1 (en) * 2019-11-04 2021-05-14 The Trustees Of Columbia University In The City Of New York High concentration cell penetrating caspase inhibitor conjugates compositions and methods thereof
AU2020395323A1 (en) * 2019-12-06 2022-06-30 The Children's Hospital Of Philadelphia Compositions and methods for modulating factor VIII function

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59172425A (ja) * 1983-03-18 1984-09-29 Nippon Chemiphar Co Ltd 新規な血液凝固因子誘導体およびその製造法ならびにそれを含有する血液凝固促進剤
US7138505B1 (en) 1984-01-12 2006-11-21 Novartis Vaccines And Diagnostics, Inc. Factor VIII:C nucleic acid molecules
US4970300A (en) 1985-02-01 1990-11-13 New York University Modified factor VIII
US5451521A (en) 1986-05-29 1995-09-19 Genetics Institute, Inc. Procoagulant proteins
US5422260A (en) 1986-05-29 1995-06-06 Genetics Institute, Inc. -Legal Affairs Human factor VIII:c muteins
EP0294910B1 (de) 1987-06-12 1996-09-11 Immuno Ag Proteine mit Faktor-VIII-Aktivität, Verfahren zu deren Herstellung unter Verwendung von genetisch modifizierten Zellen und diese enthaltende pharmazeutische Zusammensetzungen
US6346513B1 (en) 1987-06-12 2002-02-12 Baxter Trading Gmbh Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
IE69026B1 (en) 1987-06-12 1996-08-07 Immuno Ag Novel proteins with factor VIII activity process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
AU2473388A (en) * 1987-11-16 1989-06-22 Scripps Clinic And Research Foundation Treatment of factor viii inhibitors
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
SE465222C5 (sv) 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
US5766897A (en) 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
US6376463B1 (en) 1992-04-07 2002-04-23 Emory University Modified factor VIII
US6037452A (en) 1992-04-10 2000-03-14 Alpha Therapeutic Corporation Poly(alkylene oxide)-Factor VIII or Factor IX conjugate
KR100303872B1 (ko) 1992-10-02 2001-11-22 크리스터 발스트룀, 프레드릭 베르그, 하랄트 알름 응고인자ⅷ제형을포함하는조성물,이것의제조방법및안정화제로서의계면활성제의사용방법
WO1994015625A1 (en) 1993-01-15 1994-07-21 Enzon, Inc. Factor viii - polymeric conjugates
SE504074C2 (sv) 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
AU685187B2 (en) 1993-10-29 1998-01-15 Incyte Pharmaceuticals, Inc. Chimeric proteins including protease nexin-1 variants
IL113010A0 (en) 1994-03-31 1995-10-31 Pharmacia Ab Pharmaceutical formulation comprising factor VIII or factor ix with an activity of at least 200 IU/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
BE1008491A3 (fr) * 1994-07-14 1996-05-07 Croix Rouge De Belgique Depart Sequence polypeptidique antigenique du facteur viii, fragments et/ou epitopes de celle-ci.
CA2204726A1 (en) 1994-11-09 1996-12-27 Robin E. Offord Functionalized polymers for site-specific attachment
WO1997001197A1 (en) * 1995-06-21 1997-01-09 Motorola Inc. Method and antenna for providing an omnidirectional pattern
AU6486196A (en) 1995-07-11 1997-02-10 Chiron Corporation Novel factor viii:c polypeptide analogs with altered protease sites
SE9503380D0 (sv) * 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
AT403438B (de) 1996-05-24 1998-02-25 Immuno Ag Pharmazeutische präparation mit faktor viii prokoagulationsaktivität und vwf-bindungsaktivität
US6458563B1 (en) * 1996-06-26 2002-10-01 Emory University Modified factor VIII
ATE341344T1 (de) * 1996-08-02 2006-10-15 Ortho Mcneil Pharm Inc Polypeptide mit einzelnem kovalent gebundenen n- terminalen wasserlöslichen polymer
CA2225189C (en) 1997-03-06 2010-05-25 Queen's University At Kingston Canine factor viii gene, protein and methods of use
AU751898B2 (en) 1997-07-14 2002-08-29 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins
US6753165B1 (en) * 1999-01-14 2004-06-22 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
CA2306629A1 (en) * 1997-10-17 1999-04-29 Harvest Technologies Corporation Precipitation of growth-factor-enriched fibrinogen concentrate from platelet rich plasma
EP0922446A1 (de) 1997-12-03 1999-06-16 Applied Research Systems Ars Holding N.V. Lösungsphase Verfahrung zur ortspezifischer Herstellung von GRF-PEG Konjugaten
PT1079805E (pt) 1998-04-27 2005-03-31 Opperbas Holding Bv Composicao farmaceutica compreendendo factor viii e lipossomas neutros
US6759216B1 (en) 1998-11-06 2004-07-06 Emory University Glycosylated, low antigenicity low immunogenicity factor VIII
CA2349468C (en) 1998-11-10 2013-07-09 Baxter Aktiengesellschaft Factor viii polypeptide having factor viii:c activity
US6136599A (en) 1998-12-10 2000-10-24 Bayer Corporation Human hybrid host cell for mammalian gene expression
US6358703B1 (en) 1998-12-10 2002-03-19 Bayer Corporation Expression system for factor VIII
KR100731826B1 (ko) 1999-01-14 2007-06-22 볼더 바이오테크놀로지 인코퍼레이티드 유리 시스테인 잔기를 함유하는 단백질의 제조 방법
WO2000071714A2 (en) 1999-05-24 2000-11-30 The American National Red Cross Methods of reducing factor viii clearance and compositions therefor
CA2397347C (en) * 2000-02-11 2011-07-12 Maxygen Aps Factor vii or viia-like molecules
WO2002024723A1 (en) 2000-09-19 2002-03-28 Emory University Modified factor viii
AU2002248329B2 (en) 2001-01-12 2007-06-28 The American National Red Cross Methods and compositions for reducing heparan sulfate proteoglycan-mediated clearance of factor VIII
AU2002249096B2 (en) * 2001-03-22 2007-06-28 Novo Nordisk Health Care Ag Coagulation factor VII derivatives
AU2002312660A1 (en) 2001-05-31 2002-12-16 D. Collen Research Foundation Vzw Onderwijsen Navorsing Campus Gasthuisberg K.U. Leuven Recombinant molecules with reduced immunogenicity, methods and intermediates for obtaining them and their use in pharmaceutical compositions and diagnostic tools
WO2002096454A1 (en) 2001-05-31 2002-12-05 D. Collen Research Foundation Vzw Recombinant molecules with reduced immunogenicity, methods and intermediates for obtaining them and their use in pharmaceutical compositions and diagnostic tools
US7205278B2 (en) 2001-06-14 2007-04-17 The Scripps Research Institute Stabilized proteins with engineered disulfide bonds
ES2319745T3 (es) 2001-10-05 2009-05-12 Expression Therapeutics, Llc Secuencias de acidos nucleicos y aminoacidos que codifican polipeptidos de factor viii de alto nivel de expresion, y metodos de uso.
CN1646564A (zh) 2002-04-18 2005-07-27 默克专利有限公司 修饰的因子ⅷ
JP4412461B2 (ja) 2002-11-20 2010-02-10 日油株式会社 修飾された生体関連物質、その製造方法および中間体
US8003117B2 (en) 2002-11-20 2011-08-23 Nof Corporation Polyalkylene glycol derivative and modified bio-related substance
JP4490369B2 (ja) 2002-12-31 2010-06-23 ネクター セラピューティクス アラバマ，コーポレイション マレアミド酸ポリマー誘導体及びこれらの生物学的複合体
US7432330B2 (en) 2002-12-31 2008-10-07 Nektar Therapeutics Al, Corporation Hydrolytically stable maleimide-terminated polymers
ATE485331T1 (de) 2003-01-06 2010-11-15 Nektar Therapeutics Thiolselektive wasserlösliche polymerderivate
HUE058897T2 (hu) * 2003-02-26 2022-09-28 Nektar Therapeutics Polimer VIII-as faktor egység konjugátumok
US20040180054A1 (en) 2003-03-13 2004-09-16 Hanmi Pharm. Co., Ltd. Physiologically active polypeptide conjugate having prolonged in vivo half-life
US20050176108A1 (en) 2003-03-13 2005-08-11 Young-Min Kim Physiologically active polypeptide conjugate having prolonged in vivo half-life
DE602004028725D1 (de) 2003-05-12 2010-09-30 Affymax Inc Neue poly(ethylenglycol) modifizierte erythropoietinagonisten und deren verwendungen
CN1747748B (zh) 2003-05-23 2011-01-19 尼克塔治疗公司 具有特定原子排列的聚合物衍生物
EP1502921A1 (de) 2003-07-29 2005-02-02 ZLB Behring GmbH Rekombinanter mutierter menschlicher Factor VIII (FVIII) mit verbesserter Stabilität
WO2005046583A2 (en) 2003-10-30 2005-05-26 Emory University Modified fviii having reduced immunogenicity through mutagenesis of a2 and c2 epitopes
US7211559B2 (en) 2003-10-31 2007-05-01 University Of Maryland, Baltimore Factor VIII compositions and methods
AU2004296768B2 (en) 2003-12-03 2010-06-24 University Of Rochester Recombinant factor VIII having increased specific activity
WO2006027111A1 (en) 2004-09-06 2006-03-16 Zlb Behring Gmbh Modified coagulation factor viii with enhanced stability
ES2821832T3 (es) 2004-11-12 2021-04-27 Bayer Healthcare Llc Modificación de FVIII dirigida al sitio
JP2008534559A (ja) 2005-04-01 2008-08-28 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 血液凝固ｆｖｉｉｉ類似体
NZ572050A (en) * 2006-03-31 2011-09-30 Baxter Int Factor VIII conjugated to polyethylene glycol
US7645860B2 (en) * 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates

Also Published As

Publication number Publication date
NL300989I2 (nl) 2019-11-28
AU2005304622A1 (en) 2006-05-18
BRPI0517795B1 (pt) 2020-03-31
UA95225C2 (ru) 2011-07-25
RU2007121517A (ru) 2008-12-20
LUC00118I2 (de) 2019-12-27
EP2371856A2 (de) 2011-10-05
CN101124331B (zh) 2013-04-24
EP2772500A1 (de) 2014-09-03
CN103102406A (zh) 2013-05-15
IL182903A0 (en) 2007-08-19
KR20180110192A (ko) 2018-10-08
PT2363414T (pt) 2022-08-04
NL300989I1 (nl) 2019-05-22
CY2019024I1 (el) 2019-11-27
EP1824988A4 (de) 2008-12-31
CN103102406B (zh) 2015-05-27
FR19C1031I2 (fr) 2020-06-05
EP2371856B1 (de) 2022-05-18
PT3130601T (pt) 2020-10-01
AU2005304622B2 (en) 2012-03-29
HK1218718A1 (zh) 2017-03-10
PL2363414T3 (pl) 2022-09-05
DK2371856T3 (en) 2022-08-08
LT2363414T (lt) 2022-10-25
HRP20180481A2 (hr) 2018-06-29
PH12014500352B1 (en) 2019-09-25
CN103214569A (zh) 2013-07-24
US20100081615A1 (en) 2010-04-01
NO20072997L (no) 2007-06-27
EP2772500B1 (de) 2019-12-25
NO20200044A1 (no) 2007-06-27
WO2006053299A2 (en) 2006-05-18
NO20210454A1 (no) 2007-06-27
SI2363414T1 (sl) 2022-09-30
BR122016022033B1 (pt) 2021-03-02
US20160051633A1 (en) 2016-02-25
KR20140091618A (ko) 2014-07-21
PT2371856T (pt) 2022-08-12
BR122016022033B8 (pt) 2021-05-25
MX2007005466A (es) 2007-10-19
KR101243564B1 (ko) 2013-03-27
EP1824988B1 (de) 2017-04-19
FR19C1031I1 (de) 2019-06-28
JP2008524117A (ja) 2008-07-10
EP3243833A1 (de) 2017-11-15
IL182903A (en) 2014-09-30
MA29663B1 (fr) 2008-08-01
KR20130036780A (ko) 2013-04-12
ES2930159T3 (es) 2022-12-07
JP6018238B2 (ja) 2016-11-02
KR20070110260A (ko) 2007-11-16
PH12019501613A1 (en) 2020-09-14
EP3243833B1 (de) 2020-06-17
LUC00118I1 (de) 2019-05-13
BRPI0517795B8 (pt) 2021-05-25
SI3130601T1 (sl) 2020-11-30
EP2363414A2 (de) 2011-09-07
PH12014500352A1 (en) 2015-07-20
JP2017101028A (ja) 2017-06-08
HUE059193T2 (hu) 2022-10-28
NO345800B1 (no) 2021-08-09
HUS1900026I1 (hu) 2022-04-28
JP2013067621A (ja) 2013-04-18
HK1182121A1 (en) 2013-11-22
HRP20070268B1 (hr) 2018-04-20
IL232540A (en) 2017-08-31
EP3323829A1 (de) 2018-05-23
CN103214569B (zh) 2016-12-28
HRP20180481B1 (hr) 2022-02-18
PT1824988T (pt) 2017-07-21
NZ555032A (en) 2010-02-26
EP3130601A1 (de) 2017-02-15
KR101904630B1 (ko) 2018-10-04
IL234433B (en) 2019-11-28
SI2371856T1 (sl) 2022-09-30
EP3243834A1 (de) 2017-11-15
CY1123384T1 (el) 2021-12-31
HUE060016T2 (hu) 2023-01-28
EP2371856A3 (de) 2012-03-14
CN105148287A (zh) 2015-12-16
SI1824988T1 (sl) 2017-11-30
IL232540A0 (en) 2014-06-30
MX392760B (es) 2025-03-24
NO344606B1 (no) 2020-02-10
RU2423380C2 (ru) 2011-07-10
PL2371856T3 (pl) 2022-08-22
EP3323829B1 (de) 2020-07-15
KR20140019489A (ko) 2014-02-14
KR101483917B1 (ko) 2015-01-16
LTC1824988I2 (lt) 2021-02-25
ES2930143T3 (es) 2022-12-07
US9364520B2 (en) 2016-06-14
KR101468345B1 (ko) 2014-12-03
ZA200703696B (en) 2008-08-27
LT2371856T (lt) 2022-08-25
BRPI0517795A (pt) 2008-10-21
ES2633916T3 (es) 2017-09-26
JP2017105773A (ja) 2017-06-15
DK1824988T3 (en) 2017-08-07
HRP20070268A2 (en) 2007-09-30
ES2821832T3 (es) 2021-04-27
HK1117875A1 (en) 2009-01-23
CA2586379C (en) 2012-04-03
CY2019024I2 (el) 2019-11-27
CN107082806A (zh) 2017-08-22
CY1119292T1 (el) 2018-02-14
US20130274445A1 (en) 2013-10-17
JP2015134780A (ja) 2015-07-27
PL1824988T3 (pl) 2018-01-31
JP6559642B2 (ja) 2019-08-14
KR20160105928A (ko) 2016-09-07
EP3130601B1 (de) 2020-07-15
KR20120136413A (ko) 2012-12-18
JP6109523B2 (ja) 2017-04-05
EP1824988A2 (de) 2007-08-29
CN105753968A (zh) 2016-07-13
EP2363414A3 (de) 2012-03-21
WO2006053299A3 (en) 2006-08-24
CN105148287B (zh) 2019-07-09
US9096656B2 (en) 2015-08-04
HUE033776T2 (en) 2018-01-29
CN101124331A (zh) 2008-02-13
LTPA2019509I1 (lt) 2019-08-26
EP2363414B1 (de) 2022-05-18
US7632921B2 (en) 2009-12-15
HN2007015683A (es) 2011-07-11
KR101654011B1 (ko) 2016-09-05
JP6487895B2 (ja) 2019-03-20
HUE050542T2 (hu) 2020-12-28
LT1824988T (lt) 2017-10-25
DK2363414T3 (da) 2022-08-08
CA2586379A1 (en) 2006-05-18
BRPI0517795A8 (pt) 2018-12-26
EP3153181A1 (de) 2017-04-12
US20060115876A1 (en) 2006-06-01
MX350293B (es) 2017-09-04
LT3130601T (lt) 2020-09-10

Similar Documents

Publication Publication Date Title
BE2024C508I2 (de)
BE2023C542I2 (de)
BE2022C549I2 (de)
BE2021C001I2 (de)
BE2020C513I2 (de)
BE2020C517I2 (de)
BE2019C540I2 (de)
BE2019C523I2 (de)
BE2019C548I2 (de)
BE2019C506I2 (de)
BE2018C045I2 (de)
BE2020C525I2 (de)
BE2017C063I2 (de)
BE2017C027I2 (de)
BE2015C014I2 (de)
BE2014C071I2 (de)
BE2015C015I2 (de)
BE2014C064I2 (de)
BE2014C063I2 (de)
BE2014C010I2 (de)
BE2014C014I2 (de)
BE2013C071I2 (de)
BE2013C021I2 (de)
BE2012C025I2 (de)
JP2005161054A5 (de)